Back to search

Switzerland· 67103001

Spravato, Nasenspray, Lösung

A esketamine product containing esketaminum, registered in Switzerland by Janssen-Cilag AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC N06AX27

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedSpravato, Nasenspray, LösungATCN06AX27REGISTER NO.67103001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Esketamine is registered in 11 of 19 countries.

Countries holding a registration under ATC N06AX27 (esketamine), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 7 of them publish a price we can compare per daily dose

Esketamine · ATC N06AX27

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of esketamine costs, country by country.

Normalised to the WHO defined daily dose (8 mg), so markets compare like for like.

  • Switzerland: $66.47 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Esketamine · price per daily dose (8 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$66.47
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
esketaminum
Manufacturer
Janssen-Cilag AG
Country
Switzerland (CH)
ATC code
N06AX27
ATC class
Esketamine
Defined daily dose
8 mg, N
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680671030013
    Fl 1 Stk
    CHF 201.15

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

91 interactions on record for esketamine.

Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Esketamine · interactions on record

91 records

  • 7 severe
  • 84 moderate

Most severe, free to view

  • PhentermineA08AA01severe
  • FenfluramineA08AA02severe
  • MazindolA08AA05severe
  • FenfluramineN03AX26severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Esketamine in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All esketamine products

Authorised across Europe · EMA

The same active substance is authorised in 17 EEA countries. Names it is sold under:

  • Austria · Escetex, Eskelan
  • Belgium · Esketamine Kalceks, Vesierra
  • Germany · Esketamin, Esketamin Inresa
  • Denmark · Esketamine Orifarm, S-Ketamin Pfizer
  • Estonia · Esketex
  • Finland · Esketamine Kalceks, Esketamine Orifarm
  • France · Eskesia, Esketamine Renaudin
  • United Kingdom (Northern Ireland) · Esketamine Idd, Esketamine Kalceks
  • Croatia · Esgamda
  • Iceland · S-Ketamin Pfizer, Spravato
  • Liechtenstein · Spravato
  • Luxembourg · Vesierra
  • Latvia · Esketamine Kalceks
  • Netherlands · Esketamine Focus, Esketamine Idd
  • Norway · Ketanest, Sinmelan
  • Sweden · Esketamine Kalceks, Esketamine Orifarm
  • Slovenia · Esketamin Kalceks, Sinmelan

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/838d2a52-848a-4dd2-8b67-fef2c266259d
GET /v1/drugs/838d2a52-848a-4dd2-8b67-fef2c266259d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "esketaminum 28 mg",
  "valid_from": "2025-10-01",
  "limitations": "[{\"description\":\"SPRAVATO wird nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes zur Behandlung von Erwachsenen im Alter von 18 bis und mit 74 Jahren (zu Behandlungsbeginn) mit einer schweren therapieresistenten Episode einer Major Depression, die nach mindestens 2 verschiedenen Antidepressiva und 1 Augmentationsversuch (mit Lithium oder einem atypischen Antipsychotikum) weiterhin Episoden einer Major Depression aufweisen mit einem CGI-S Wert von ≥5 und bei denen eine interventionelle Therapie, wie die Elektrokonvulsionstherapie (EKT), zurzeit nicht angezeigt ist, vom Patienten abgelehnt wird oder die Patienten keinen Zugang zu einer solchen Therapie haben, in Kombination mit einem oralen Antidepressivum, vergütet. Vor Beginn der Behandlung muss der Schweregrad der depressiven Störung mit einem Wert auf der Clinical Global Impression Scale (CGI-S) von ≥5 bestätigt werden.<br> \\nDie initiale Kostengutsprache wird für einen Zeitraum von 4 Wochen erteilt. Bei einem anhaltenden, nachgewiesenen Ansprechen nach 4 Wochen entsprechend einer Verbesserung des CGI-S um ≥2 Punkte bei 2 Beurteilungen innerhalb der Behandlungswochen 3 und 4 kann die Kostengutsprache um 3 Monate verlängert werden. Danach kann die Kostengutsprache bei weiter anhaltendem, nachgewiesenem Ansprechen noch maximal zweimal um je 3 Monate verlängert werden. SPRAVATO wird maximal während 10 Monaten vergütet.<br> \\nDie Verschreibung von SPRAVATO erfolgt ausschliesslich durch Fachärzte der Psychiatrie und Psychotherapie an vom BAG definierten Zentren, bei denen es sich um Institutionen mit einem kantonalen Leistungsauftrag für die psychiatrische Versorgung von Erwachsenen handelt (Liste siehe http://www.bag.admin.ch/sl-ref).<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-10-01\",\"validTo\":\"2028-09-30\"}]",
  "galenic_form": "Nasenspray 28 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2022-10-01",
  "self_retention_pct": 10
}

See everything about esketamine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.